Scarica l'app Stockscreener
395.12
0.59%
-2.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex to Participate in Upcoming September Investor Conferences - Business Wire
What's Wrong With Vertex Pharmaceuticals Stock? - MSN
Stock Analysis | Vertex Pharmaceuticals OutlookStrong Technicals and Mixed Analyst Sentiment - AInvest
Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug - MSN
Goldman Sachs Reiterated a Buy Rating on Vertex Pharmaceuticals (VRTX), Kept the PT Unchanged - Yahoo Finance
Living life with cystic fibrosis: The Circle of Care grant - Vertex Pharmaceuticals
Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More - Seeking Alpha
Vertex Pharmaceuticals: Promising Growth with Successful Launch and Strong Pipeline - TipRanks
Top 3 Growth Stocks to Buy in August: Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals - AInvest
Vertex Pharmaceuticals Inc: Financial Performance and Competitive Strengths - AInvest
Vertex Pharmaceuticals and Netflix: High-Conviction Growth Buys in a Volatile Market - AInvest
Vertex Pharma CEO Buys the Stock Dip - Barron's
Up and down the ladder: The latest comings and goings - statnews.com
Is This Beaten-Down Stock a Buy on the Dip? - AOL.com
Vertex Inc. Downgrade: Near-Term Growth Expectations Reset - AInvest
Joint Venture Receives $1B Refinancing for Vertex Pharmaceuticals Headquarters Facility in Boston - REBusinessOnline
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $430 From $530, Maintains Buy Rating - MarketScreener
VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market - Yahoo Finance
The 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
Vertex Pharmaceuticals: Undervalued After Pain Drug Setbacks - AInvest
Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet (NASDAQ:VRTX) - Seeking Alpha
Vertex HQ refinanced for $1 billion - The Business Journals
Vertex Pharmaceuticals Soars 3.44%—What’s Fueling This Biotech Breakout? - AInvest
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), AMN Healthcare Services (AMN) - The Globe and Mail
Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings May Just Be The Starting Point - Yahoo Finance
Vertex Pharmaceuticals: A Biotech Powerhouse Poised for Rebound After Oversold Correction - AInvest
Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade) (NASDAQ:VRTX) - Seeking Alpha
Goldman Sachs reiterates Buy rating on Vertex stock, citing diversification By Investing.com - Investing.com South Africa
Vertex Pharma announces new share buybacks worth up to $4B - MSN
The week in pharma: action, reaction and insight – week to August 8 - The Pharma Letter
Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial - MSN
Brazil’s Antitrust Watchdog Probes Soybean Traders Over Cartel Concerns - PYMNTS.com
Vertex unveils positive study data for CF triple-combination regimens; shares jump - FirstWord Pharma
KOL Views: Vertex's triplet data exceed expectations – implications for CF landscape - firstwordpharma.com
Vertex Analyst Rating Lowered by B of A Securities; VERX Stock Price Target Cut to $34.00 - AInvest
Moving Average Crossover Confirms Uptrend in Vertex Pharmaceuticals IncorporatedMarket Surge Signal for Swing Traders Triggered - beatles.ru
Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat - MSN
South African Patient Groups Urge Antitrust Probe into Vertex Pharmaceuticals Over Cystic Fibrosis Drug Pricing - geneonline.com
Hedge Fund and Insider Trading News: Ken Griffin, DE Shaw, Bobby Jain, Jim Cramer, Rokos Capital Management, Point72 Asset Management, Vertex Pharmaceuticals Inc (VRTX), Galaxy Digital Inc (GLXY), and More - Insider Monkey
Vertex Pharmaceuticals shares fall 2.75% intraday after insider bought shares and $1.0 billion mortgage financing. - AInvest
Vertex Pharmaceuticals Plunges 2.69%—Is This the Bottom for Vertex Pharmaceuticals? - AInvest
Advocates urge South Africa to reopen antitrust probe into Vertex Pharmaceuticals - statnews.com
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals' Headquarters in Boston Seaport District - MarketScreener
Vertex Pharma CEO Kewalramani buys shares worth $3.89 million - Investing.com
RMR Group secures $1 billion mortgage for Vertex Pharmaceuticals HQ By Investing.com - Investing.com Australia
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District - MarketScreener
Vertex Pharmaceuticals Executives Make Significant Stock Purchases - TradingView
$1B Deal: RMR Group Refinances Vertex Pharma's Boston HQ with 15-Year Lease Extension - Stock Titan
Vertex Pharmaceuticals Reports Q2 2025 Revenue Growth, Net Income Turns Positive Amidst Challenges - AInvest
Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Vertex Pharmaceuticals: Guggenheim maintains a 'Buy' Rating, The Target Price is $546 - AInvest
The Escalator: Geron, Vertex Pharmaceuticals, Butler/Till and more - Medical Marketing and Media
Vertex Pharmaceuticals Shares Rise After Upgrade From Wells Fargo - MarketScreener
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Vertex stock price target lowered to $411 by Canaccord on mixed pipeline updates - Investing.com
Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Vertex tops estimates on cystic fibrosis treatment strength, new products - MSN
Vertex’s Journavx successor culled after falling short in Phase II trial - Clinical Trials Arena
1.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):